John Overdeck’s Viridian Therapeutics VRDN Stock Holding History

John Overdeck’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,114	Closed	-$687K	–	5467
2026 Q1	$687K	Buy	+35,114	New	+$1.04M	﹤0.01%	3511
2025 Q4	–	Sell	-22,011	Closed	-$475K	–	4458
2025 Q3	$475K	Sell	22,011 -47,966	-69%	-$865K	﹤0.01%	3010
2025 Q2	$978K	Sell	69,977 -152,422	-69%	-$2.07M	﹤0.01%	2265
2025 Q1	$3M	Sell	222,399 -202,138	-48%	-$3.44M	0.01%	1462
2024 Q4	$8.14M	Sell	424,537 -57,599	-12%	-$1.25M	0.02%	849
2024 Q3	$11M	Buy	482,136 +62,316	+15%	+$1.02M	0.02%	718
2024 Q2	$5.46M	Buy	419,820 +192,966	+85%	+$2.67M	0.01%	972
2024 Q1	$3.97M	Buy	+226,854	New	+$4.4M	0.01%	1098
2023 Q3	–	Sell	-21,018	Closed	-$500K	–	3239
2023 Q2	$500K	Buy	+21,018	New	+$539K	﹤0.01%	2331

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

John Overdeck's VRDN Position: Q2 2026 in Review

John Overdeck sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 35,114 shares — an estimated $687K sold.

John Overdeck first reported a position in VRDN in Q2 2023 and held it in 9 quarters. The position peaked at $11M in Q3 2024. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

John Overdeck reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
John Overdeck sold 35,114 Viridian Therapeutics shares in Q2 2026, an estimated $687K.
John Overdeck first reported a position in Viridian Therapeutics in Q2 2023 and held it in 9 quarters.
John Overdeck's Viridian Therapeutics position peaked at $11M in Q3 2024.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.